Upgrade to SI Premium - Free Trial

NeOnc schedules FDA meeting for NEO212 Phase 2 design review

September 28, 2026 8:01 AM
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) announced it is scheduled to meet with the U.S. Food and Drug Administration on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA